Manmeet S. Ahluwalia
YOU?
Author Swipe
View article: Supplementary Tables S1-S2 from Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma
Supplementary Tables S1-S2 from Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma Open
Table S1. qPCR primers used for mouse study Table S2. qPCR primers used for human study
View article: Supplementary Figures S1-S16 from Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma
Supplementary Figures S1-S16 from Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma Open
Supplementary Fig. S1. Immune cell-dependent survival differences between males and females in murine glioblastoma models. Supplementary Fig. S2. Mouse syngeneic GBM cell lines do not contain a Y chromosome. Supplementary Fig. S3. Frequenc…
View article: Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609)
Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609) Open
Purpose: To evaluate the efficacy and safety of dual immune checkpoint inhibitors (ICI) in patients with brain metastases (BM) from rare cancers. Patients and Methods: Patients with and without BM received nivolumab (240 mg every two weeks…
View article: Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial
Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial Open
View article: CTIM-29. TOXICITY PROFILE OF DUAL IMMUNE CHECKPOINT BLOCKADE IN MELANOMA BRAIN METASTASES: A META-ANALYSIS OF GRADE ≥3 AND IMMUNE-RELATED ADVERSE EVENTS
CTIM-29. TOXICITY PROFILE OF DUAL IMMUNE CHECKPOINT BLOCKADE IN MELANOMA BRAIN METASTASES: A META-ANALYSIS OF GRADE ≥3 AND IMMUNE-RELATED ADVERSE EVENTS Open
BACKGROUND Dual checkpoint blockade with nivolumab and ipilimumab (NIVO+IPI) is a therapy for melanoma brain metastases (MBM), but data on severe and immune-related toxicities remain limited. This meta-analysis examined the incidence and v…
View article: IMG-131. Radiomics-based Risk-stratification of Brain Metastases: Preliminary Findings
IMG-131. Radiomics-based Risk-stratification of Brain Metastases: Preliminary Findings Open
PURPOSE Brain metastasis (BM) is known for poor survival with ~10% of all cancer patients developing BM at some point in the treatment course. Reliably predicting patient survival is essential for tailoring treatments. Unfortunately, exist…
View article: INNV-42. Survival benefit of targeted therapy in EGFR-mutant NSCLC patients with leptomeningeal metastases
INNV-42. Survival benefit of targeted therapy in EGFR-mutant NSCLC patients with leptomeningeal metastases Open
BACKGROUND Leptomeningeal disease (LMD) is a rare but devastating complication of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations. Its natural history is marked by neurologic decline and poor survival, with…
View article: DISP-35. Origin-Based Differences in Outcomes Among Hispanic Patients with Glioblastoma
DISP-35. Origin-Based Differences in Outcomes Among Hispanic Patients with Glioblastoma Open
BACKGROUND Hispanic individuals in the United States harbor distinct cultural, socioeconomic, and health profiles that may influence cancer outcomes. While disparities have been observed in other malignancies, the role of specific Hispanic…
View article: CTIM-28. INTRACRANIAL AND SYSTEMIC EFFICACY OF DUAL IMMUNE CHECKPOINT BLOCKADE (NIVOLUMAB AND IPILIMUMAB) IN MELANOMA BRAIN METASTASES: A META-ANALYSIS
CTIM-28. INTRACRANIAL AND SYSTEMIC EFFICACY OF DUAL IMMUNE CHECKPOINT BLOCKADE (NIVOLUMAB AND IPILIMUMAB) IN MELANOMA BRAIN METASTASES: A META-ANALYSIS Open
BACKGROUND Checkpoint inhibitors have transformed outcomes in melanoma, with promising evidence of intracranial activity. This meta-analysis evaluates the efficacy of combination immunotherapy with nivolumab and ipilimumab (NIVO+IPI) in pa…
View article: CTIM-04. A PHASE II STUDY OF AZELIRAGON IN COMBINATION WITH RADIATION THERAPY IN NEWLY DIAGNOSED PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA
CTIM-04. A PHASE II STUDY OF AZELIRAGON IN COMBINATION WITH RADIATION THERAPY IN NEWLY DIAGNOSED PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA Open
BACKGROUND Myeloid-derived suppressor cells (MDSCs) contribute to immunosuppression and treatment resistance in glioblastoma (GBM). A prior phase I study showed that phosphodiesterase-5 inhibition during chemoradiotherapy reduced periphera…
View article: SURG-98. Clinical outcomes, operational metrics, and translational insights derived from trials of MR-guided, transcranial, microbubble-enhanced focused ultrasound for brain tumors: a 2010-2025 evidence analysis
SURG-98. Clinical outcomes, operational metrics, and translational insights derived from trials of MR-guided, transcranial, microbubble-enhanced focused ultrasound for brain tumors: a 2010-2025 evidence analysis Open
INTRODUCTION Multi-factorial, complex challenges exist in developing actionable diagnostics and effective therapies for brain malignancies. Approaches that leverage biological underpinnings are increasingly recognized as necessary. Several…
View article: CTIM-26. TOXICITY PROFILE OF CAR-T CELL THERAPY IN GLIOBLASTOMA: A META-ANALYSIS OF CYTOKINE RELEASE SYNDROME, NEUROTOXICITY, AND ADVERSE EVENTS
CTIM-26. TOXICITY PROFILE OF CAR-T CELL THERAPY IN GLIOBLASTOMA: A META-ANALYSIS OF CYTOKINE RELEASE SYNDROME, NEUROTOXICITY, AND ADVERSE EVENTS Open
BACKGROUND Chimeric antigen receptor (CAR) T cell therapy is under investigation for glioblastoma (GBM), with early-phase trials reporting varied toxicity profiles. While CAR-T has demonstrated potential in hematologic malignancies, its sa…
View article: BIOM-23. EVALUATING THE MOLECULAR CONCORDANCE BETWEEN LIQUID BIOPSY AND BRAIN METASTASIS TISSUE IN PATIENTS WITH BRAIN METASTASES
BIOM-23. EVALUATING THE MOLECULAR CONCORDANCE BETWEEN LIQUID BIOPSY AND BRAIN METASTASIS TISSUE IN PATIENTS WITH BRAIN METASTASES Open
BACKGROUND Management of patients with brain metastases requires knowledge of the molecular profile of the disease. Although molecular discordance between systemic disease and brain metastases is recognized, the extent to which peripheral …
View article: DISP-39. Clinical Characteristics and Survival Outcomes Among Male Breast Cancer Patients with Brain Metastases: A Retrospective Analysis
DISP-39. Clinical Characteristics and Survival Outcomes Among Male Breast Cancer Patients with Brain Metastases: A Retrospective Analysis Open
BACKGROUND Male breast cancer is uncommon, accounting for approximately 1% of cancers that occur in men and 1% of all breast cancers worldwide. Due to its rarity, the clinical course and treatment of male breast cancer remain poorly define…
View article: NCOG-47. Real-world impact of immunotherapy on survival in melanoma patients with brain metastases: a population-based study in the United States
NCOG-47. Real-world impact of immunotherapy on survival in melanoma patients with brain metastases: a population-based study in the United States Open
BACKGROUND Melanoma brain metastases (MBM) are associated with high mortality. While immunotherapy has become a standard of care in melanoma, its real-world impact on survival in patients with brain involvement remains less studied. METHOD…
View article: The Efficacy and Safety of Beta-blockers and Immune Checkpoint Inhibitors in Patients with Cancer: A Systematic Review and Meta-analysis
The Efficacy and Safety of Beta-blockers and Immune Checkpoint Inhibitors in Patients with Cancer: A Systematic Review and Meta-analysis Open
Despite positive preclinical findings, this meta-analysis showed that adding BBs to ICIs was not associated with longer survival. We await the results of ongoing prospective trials assessing this strategy. PROSPERO REGISTRATION: CRD4202457…
View article: CTIM-25. CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY FOR GLIOBLASTOMA: A META-ANALYSIS OF EFFICACY FROM EARLY-PHASE CLINICAL TRIALS
CTIM-25. CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY FOR GLIOBLASTOMA: A META-ANALYSIS OF EFFICACY FROM EARLY-PHASE CLINICAL TRIALS Open
BACKGROUND Chimeric antigen receptor (CAR) T cell therapies represent a promising but still investigational approach for glioblastoma (GBM), a malignancy with limited effective treatment options. Despite interest, clinical outcomes remain …
View article: EPCO-62. ASSESSMENT OF AGE IN THE CLINICAL RISK STRATIFICATION OF PATIENTS WITH IDH-MUTANT GLIOMAS
EPCO-62. ASSESSMENT OF AGE IN THE CLINICAL RISK STRATIFICATION OF PATIENTS WITH IDH-MUTANT GLIOMAS Open
BACKGROUND Isocitrate dehydrogenase mutant (IDHm) low-grade gliomas have a slow growing phase, but eventually become aggressive tumors. To delay long-term toxic effects of chemoradiation, low-risk patients are monitored after surgery. Trad…
View article: DISP-27. Temporal trends, treatment strategies, and survival disparities in melanoma brain metastases: insights from a 12-year real-world cohort
DISP-27. Temporal trends, treatment strategies, and survival disparities in melanoma brain metastases: insights from a 12-year real-world cohort Open
BACKGROUND Melanoma brain metastases (MBM) present a significant clinical challenge, historically associated with poor prognosis. This study aimed to evaluate temporal trends, treatment patterns, and survival outcomes among patients with M…
View article: Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM
Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM Open
Glioblastoma (GBM) has proved difficult to treat, and there is dire need for more effective therapies. In a single arm phase IIa trial (NCT02455557), treatment of newly diagnosed GBM patients with the peptide vaccine SurVaxM resulted in pr…
View article: Author Correction: Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care
Author Correction: Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care Open
View article: OS04.5.A A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209
OS04.5.A A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209 Open
BACKGROUND FGFR genomic alterations occur in approximately 8% of gliomas. Inhibition of FGFR1-3 with pemigatinib showed antitumor activity in a multihistology basket trial (FIGHT-207) in which approximately 10% of participants (pts) had re…
View article: Intracranial metastases from solid tumors: Call to Action and Consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology Collaborative
Intracranial metastases from solid tumors: Call to Action and Consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology Collaborative Open
Intracranial metastases (ICM), specifically parenchymal brain metastases, remain a major clinical challenge in solid tumor oncology, despite recent advances in cancer therapies which have led to improvements in survival for these patients.…
View article: A nomogram to predict development of brain metastasis in non-small cell lung cancer patients: a retrospective analysis using routinely available medical records
A nomogram to predict development of brain metastasis in non-small cell lung cancer patients: a retrospective analysis using routinely available medical records Open
View article: Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions Open
Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict gliobl…
View article: CTLT-04 SAFETY AND PRELIMINARY EVIDENCE OF A THERAPEUTIC EFFECT OF AZELIRAGON COMBINED WITH STEREOTACTIC RADIATION THERAPY IN PATIENTS WITH BRAIN METASTASES: PHASE 1 STUDY RESULTS
CTLT-04 SAFETY AND PRELIMINARY EVIDENCE OF A THERAPEUTIC EFFECT OF AZELIRAGON COMBINED WITH STEREOTACTIC RADIATION THERAPY IN PATIENTS WITH BRAIN METASTASES: PHASE 1 STUDY RESULTS Open
Azeliragon is an oral, brain-penetrating small molecule inhibitor of the receptor for advanced glycation end-products (RAGE), reducing neuroinflammation by inhibiting peritumoral edema/vascular leakage and overcoming radiation resistance. …
View article: Supplemental Figure 2 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
Supplemental Figure 2 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy Open
Supplemental Figure 2 shows the cumulative incidence functions of brain metastases and death in all three cohorts.
View article: NCTQ-05 FUNCTIONAL AND NEUROCOGNITIVE OUTCOMES AFTER MRI-GUIDED LASER INTERSTITIAL THERMAL THERAPY FOR BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
NCTQ-05 FUNCTIONAL AND NEUROCOGNITIVE OUTCOMES AFTER MRI-GUIDED LASER INTERSTITIAL THERMAL THERAPY FOR BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS Open
Laser interstitial thermal therapy (LITT) is increasingly utilized as a minimally invasive option for treating brain metastases (BM) in patients with progressive or radiosurgery-refractory disease. However, the impact of LITT on functional…
View article: Supplemental Figure 1 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
Supplemental Figure 1 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy Open
Supplemental Figure 1 shows the number of patients who were included/excluded based on study criteria.
View article: Supplemental Table 1 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
Supplemental Table 1 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy Open
Supplemental Table 1 provides an overview of the Trinetx database.